Active Biotech's drug against MS in Phase I trials 6 months ahead of plan


The SAIK compounds will be concentrated primarily on the treatment of MS, Multiple Sclerosis. The product will be orally active in contrast to the daily injections that the MS patients are treated with today.

More than 20,000 new cases of MS, often young people, are diagnosed every year. The market for new MS therapies is estimated to be very large, as only approximately 25 per cent of patients today can be treated successfully with existing therapies.

Active Biotech AB (publ)

Sven Andréasson
President and CEO